Lapatinib Completed Phase 2 Trials for Metastatic Breast Cancer (MBC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00694252Lapatinib and Circulating Tumor Cells in Breast Cancer
NCT02338245Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab